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C-reactive protein and cardiovascular disease in peritoneal di- fully explain this increased incidence of CVD [3]. Recent
alysis patients. studies support a role for non-traditional CV risk factors
Background. Elevated plasma concentrations of C-reactive
such as hyperhomocysteinemia [4], oxidative stress [5],protein (CRP) is a risk factor for cardiovascular disease (CVD)
and calcium-phosphate product [6] in the pathogenesisin the general population and in hemodialysis patients. The
prognostic value of CRP is less well known in peritoneal dialysis of cardiovascular disease in dialysis patients. Elevated
(PD) patients. We examined the association between CRP and plasma concentrations of C-reactive protein (CRP), a
cardiovascular event (CVE) in a large population of PD patients.
sensitive marker of underlying inflammation [7], haveMethods. Two hundred and forty patients starting PD were
been shown to predict an increased risk of future cardio-enrolled in this prospective study. The role of CRP was ana-
lyzed with respect to other known cardiovascular risk factors. vascular outcomes in the general population [8] as well
Results. The patients were followed for a mean duration of as in hemodialysis patients [9, 10].
41 21 months; the median value of CRP was 7 mg/L. Eighty-
The prognostic value of CRP is less well known innine cardiovascular events (CVE; 37.1%) occurred in 84 pa-
peritoneal dialysis (PD) patients. To date, only two smalltients and the CRP levels were higher in patients who experi-
enced CVE (27  14 vs. 6  8 mg/L; P  0.0001). In the Cox studies have focused on the predictive value of elevated
model, patients in the three lower quartiles of the CRP levels CRP in this population [11, 12]. The authors concluded
had a decreased risk of CVE compared with those in the highest
that CRP elevation occurred in a substantial proportionquartile. Cox regression analysis also revealed that age, a previ-
of patients and was found to be predictive of future myo-ous history of cardiovascular disease, hyperhomocysteinemia
and hypoalbuminemia were risk factors for CVE. CRP levels cardial infarction. Nevertheless, the small size of these
were higher in patients who died during the study period (25 studies population hampered the relevance of their results.
12 vs. 5  8 mg/L; P  0.003). In the Cox model, patients with
In our single center study, we prospectively examinedCRP levels above the median had an increased risk of death
the association between CRP elevation and cardiovascu-compared with those in the lowest quartile.
Conclusions. Chronic inflammation, as reflected by elevated lar event (CVE) in a large population of PD patients.
CRP levels, is frequent in patients starting PD and indepen-
dently contributes to an increased incidence of CVE in this
population. METHODS
Patient characteristics
The aim of the study was to evaluate the relevance ofDialysis patients have disproportionately high rates
of arteriosclerotic outcomes and cardiovascular (CVD) different parameters as cardiovascular risk factors in a
mortality [1, 2]. A higher prevalence of classic cardiovas- large population of patients starting peritoneal dialysis.
cular (CV) risk factors (such as smoking, hypertension, A total of 240 consecutive patients starting PD between
hypercholesterolemia, etc.) and non-modifiable risk fac- November 1994 and August 2001 were included in this
tors (such as age, sex, and family history of CVD) cannot prospective, single center study. Oral information con-
cerning the study was provided to each patient.
Key words: atherosclerosis, chronic inflammation, homocysteine, mal- Cardiovascular risk factorsnutrition, risk factors, dialysis, myocardial infarction risk.
Age, gender, weight, size, blood pressure, diabetes mel-
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Past history of CVE oro-2-oxa-1,3 diazole-4 sulfuronate, followed by 8-amino-
naphtalene-1,3,6-trisulphonic acid, and high-pressure liq-A past history of CVE was defined by: (1) coronary
uid chromatography (HPLC) separation with fluorescenceheart disease, including myocardial infarction, coronary
detection. The normal values of plasma Hcy concentra-revascularization including coronary artery bypass sur-
tion ranged from 7 to 15 mol/L. The precision of the as-gery or percutaneous transluminal coronary angioplasty,
say corresponds to a coefficient of variation 3%.typical history of angina with abnormal coronarography
or myocardial scintigraphy; (2) stroke/cerebrovascular C-reactive protein
disease, including both non-hemorrhagic and hemor-
C-reactive protein was measured by the Nephelometryrhagic strokes, and carotid endarterectomy; (3) abdomi-
Kit (Beckman, Fullerton, CA, USA).nal aortic or lower extremity arterial disease, including
abdominal aortic repair; lower extremity amputation; Renal function
intermittent claudication confirmed by Doppler or arteri-
Serum creatinine concentration and urinary proteinography findings.
excretion were measured. Creatinine clearance was cal-
culated using the Gault-Cockcroft formula.Nutritional status
The albumin concentration was determined. Body mass PTH, vitamin D, Ca, pH
index (BMI) was calculated as weight/height2.
Parathyroid hormone (PTH) was measured using an
immunoradiometric assay, with a normal range betweenSmoking behavior
15 and 80 pg/mL. Calcium and phosphorus were mea-With respect to smoking behavior, subjects were cate-
sured by standard autoanalyzer techniques.gorized as current smokers or non-smokers.
Arteriosclerotic events
Blood pressure
Coronary heart disease. Myocardial infarction docu-
Blood pressure (BP) was measured by a nurse using a mented by (1) serial 12-lead electrocardiogram evidence
semi-automatic device, based on an oscillometric method or Q-wave infarction and appropriate myocardial en-
with the patients in a sitting position after resting more zyme elevations; (2) coronary revascularization including
than five minutes. Pulse pressure [systolic BP (SBP)  coronary artery bypass surgery or percutaneous translu-
diastolic BP (DBP)] was calculated. minal coronary angioplasty; (3) typical history of angina
with abnormal coronarography.LVH
Stroke/cerebrovascular disease. Both non-hemorrhagic
Left ventricular hypertrophy (LVH) was defined by a and hemorrhagic strokes were confirmed by neurologic
Sokolow index (wave R measured in derivation V1  examination findings consistent with new onset focal neu-
wave S measured in derivation V6) 35 mm. rologic deficits, with or without computed tomography
or magnetic resonance imaging evidence of cerebral in-Lipid profile
farction. Symptomatic extracranial artery stenosis result-
Triglycerides, and total and high-density lipoprotein ing in carotid endarteriectomy was also a confirmatory
(HDL) cholesterol concentrations were measured. Low- factor.
density lipoprotein (LDL) cholesterol was calculated us- Abdominal aortic or lower extremity arterial disease.
ing the method described by Friedwald, Levy and Fred- Abdominal aortic repair; lower extremity revasculariza-
rickson [13]. tion via bypass surgery or angioplasty; lower extremity
amputation; new onset of intermittent claudication con-
Homocysteine firmed by Doppler or arteriography findings.
Total plasma homocysteine (Hcy) was measured using Two physicians independent of the study were respon-
a previously described method [14]. Briefly, venous blood sible for ascertaining cardiovascular events (CVE). This
samples were drawn after an overnight fast. The blood analysis was performed without any knowledge of the
sample was centrifuged within 15 minutes, and plasma patient’s baseline characteristics.
stored frozen at20C. Hcy concentration, the sum of the
Statistical analysisacid-soluble (that is reduced Hcy, homocysteine, disul-
phide, and homocysteine-cysteine mixed disulphide), and Arithmetic mean was calculated and expressed as SD.
protein-bound moieties was measured by high-perfor- Using log rank tests on Kaplan-Meier nonparametric
mance liquid chromatography. This assay involves the estimates of the survival without CVE distribution, we
following steps: reduction of the sample with tri-n-butyl- selected variables with a P value 	0.20. The selected
phosphine, precipitations of proteins, alkalinization of the variables were included into a Cox proportional hazards
model, and a backward stepwise selection process wassupernatant with sodium borate, derivitization with 7-flu-
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Table 2. Description of continuous variablesTable 1. Description of categorical variables
Variable Frequency (%) Variable Mean Standard deviation Median
Age years 66 17 70Gender
Male 150 (62.5%) SCr clearance mL/min 8.7 3.9 7.6
PTH pg/mL 286 199 196Female 90 (37.5%)
History of cardiovascular event Vitamin D ng/mL 11 7 12
Phosphorus mmol/L 1.75 0.53 1.68Yes 95 (39.6%)
No 145 (60.4%) Calcium mmol/L 2.17 0.19 2.23
Hemoglobin g/100 mL 10.9 1.8 12.9Tobacco consumption
Yes 58 (24%) Fibrinogen g/L 3.94 0.98 3.82
LDL cholesterol g/L 1.33 0.34 1.34No 182 (76%)
Diabetes HDL cholesterol g/L 0.36 0.22 0.32
Total serum cholesterol g/L 2.35 0.44 2.34Yes 53 (22%)
No 187 (78%) Triglycerides g/L 1.97 1.14 1.72
Serum homocysteine lmol/L 22.1 7.33 22.4Left ventricle diameter
35 mm 31 (12.9%) BMI kg/m2 25.2 4.6 25.4
SBP mm Hg 145 21 14035 mm 209 (87.1%)
DBP mm Hg 81 12 81
PP mm Hg 66 17 67
Glycemia mmol/L 6.4 1.3 6.11
CRP mg/L 9.2 8.4 7
Serum albumin g/L 37 4.4 37performed, this time at a classical 
  0.05. As gender
Abbreviations are: SCr, serum creatinine; PTH, parathyroid hormome; LDL,and age were potential confounding variables, they were
low density lipoprotein; HDL, high density lipoprotein; BMI, body mass index;
entered into the Cox model also, no matter the signifi- SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure;
CRP, C-reactive protein.cance of their relationships with CVE. Age was split into
two classes separated by its median  70 years, CRP
was split into quartiles (CRP limits 3.2, 7 and 12.9 mg/L),
and so was serum homocysteine (limits 18.4, 22.4 and Table 3. Relative risk estimates for CVD of the upper quartile of
CRP (12.9 mg/L) calculated for each class of tHcy26.8 mol/L) as well as albumin (limits 33, 37, 40 g/L).
and albumin levels
Tobacco consumption was accounted for as currently
Variable Relative riska 95% CIsmoking versus non-smoking. Variables that were split
Serum albumin g/Linto quartiles were replaced by dummy variables in the
33 (1st quartile) 5.27 (1.43; 11.98)Cox model, which tested quartile 2 versus quartile 1,
33–37 (vs. 1st quartile) 5.31 (1.79; 13.09)
quartile 3 versus quartile 1 and quartile 4 versus quartile 1. 37–40 (vs. 1st quartile) 5.63 (1.54; 13.51)
40 (vs. 1st quartile) 5.44 (1.81; 11.82)Results are expressed as relative risk (RR) and 95%
Serum homocysteine lmol/Lconfidence interval, with a P value testing the null hy- 18.4 (1st quartile) 5.34 (1.71; 12.64)
pothesis: RR  1. Therefore when the P value is less 18.4–22.4 (vs. 1st quartile) 5.53 (1.49; 11.96)
22.4–26.8 (vs. 1st quartile) 5.51 (1.77; 13.46)than 0.05, RR is significantly different from 1, either
26.8 (vs. 1st quartile) 5.29 (1.64; 12.59)
greater than 1 (that is, the risk of CVE is increased) or
a Cox model is adjusted for genderless than 1 (that is, the risk of CVE is decreased).
RESULTS
Cardiovascular events
Demographic characteristics of the population Eighty-nine CVE (37.1%) occurred in 84 patients
The patients were followed for a mean duration of (cerebrovascular disease, N 11; coronary heart disease,
41  21 months. Fourteen patients (9.9%) underwent 56; peripheral vascular disease, 22), which corresponds
renal transplantation during follow-up. Twenty-one were to 108 CVE for 1000 patient-years. Ninety-two patients
switched to hemodialysis during the study period. For (38.3%) died during follow-up, 41 (45%) of cardiovascu-
these patients, the end of the follow-up was the last day lar disease. CRP levels were higher in patients who expe-
on PD. rienced CVE (27 14 mg/L vs. 6 8 mg/L; P 0.0001).
The demographic, clinical, and biological characteris- Quartiles were defined according to CRP levels
tics of the study population are shown in Tables 1 and 2. (Table 3). There was a linear increase in the risk of CVE
The mean age was 66  17 years. Primary causes of from the lower quartile to the higher quartile of CRP
ESRD were chronic glomerulonephritis in 15%, chronic concentrations [10.5% vs. 21% in Q2 (0.0001) and vs.
interstitial nephritis in 13%, polycystic kidney disease in 33% in Q3 (0.0001), 57% in Q4 (0.0001); Fig. 1].
13%, nephroangiosclerosis in 16%, diabetes mellitus in In univariate analysis, age (P  0.0001), male gender
22%, and undetermined in 21%. Serum albumin, hemo- (P  0.01), a past history of cardiovascular disease (P 
0.0001), smoking status (P  0.03), diabetes mellitusglobin and PTH were approximately normally distributed.
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Table 4. Cox model: Relative risks (RR) of cardiovascular event
(CVE) and 95% confidence intervals
Variable Relative riska 95% CI P value
CRP g/L
3.2 (1st quartile) 1 — —
3.2–7 (vs. 1st quartile) 2.34 (1.07; 4.38) 0.022
7–12.9 (vs. 1st quartile) 3.31 (2.01; 12.01) 0.001
12.9 (vs. 1st quartile) 5.41 (1.69; 12.85) 0.008
Age years
70 1 — —
70 6.36 (1.78; 22.59) 0.001
Serum albumin g/L
33 (1st quartile) 1 — —
33–37 (vs. 1st quartile) 0.95 (0.84; 1.44) 0.24b
37–40 (vs. 1st quartile) 0.85 (0.72; 0.97) 0.041
40 (vs. 1st quartile) 0.65 (0.31; 0.89) 0.01
History of CVE
No 1 — —
Fig. 1. Proportion of patients free of cardiovascular events (CVE) Yes 5.12 (1.88; 13.54) 0.001
according to C-reactive protein (CRP) quartiles. Serum homocysteine lmol/L
18.4 (1st quartile) 1 — —
18.4–22.4 (vs. 1st quartile) 1.40 (0.81; 9.57) 0.12b
22.4–26.8 (vs. 1st quartile) 1.81 (0.94; 9.52) 0.07b
26.8 (vs. 1st quartile) 4.58 (1.73; 17.64) 0.009
(P  0.13), high phosphorus concentration (P  0.08),
a Cox model is adjusted for genderlow calcium concentration (P  0.03), high fibrinogen b Non-significant at 
  5%
concentration (P  0.07), low HDL cholesterol (P 
0.02), tHcy (P  0.0001), systolic BP (P  0.07), pulse
BP (P  0.04), glycemia (P  0.07), CRP (P  0.0001) Table 5. Cox model: Relative risks (RR) of death and 95%
confidence intervalsand low albumin concentration (P  0.003) were associ-
ated with CVE. Variable Relative riska 95% CI P value
We tested for possible interactions between CRP and
CRP g/L
tHcy on the one hand, and CRP and albumin on the 3.2 (1st quartile) 1 — —
3.2–7 (vs. 1st quartile) 1.41 (0.92; 1.41) 0.09bother. RR for CRP was calculated separately for each
7–12.9 (vs. 1st quartile) 1.82 (1.07; 3.17) 0.02tHcy class, and for each albumin class. These interactions
12.9 (vs. 1st quartile) 5.2 (1.37; 12.94) 0.009
were minor because RR did not change much with both Age years
70 years 1 — —tHcy levels and albumin concentrations, and this did not
70 years 6.11 (1.94; 17.247) 0.004modify the interpretation of the global RR (Table 3). Serum albumin g/L
After backward stepwise selection, variables that re- 33 (1st quartile) 1 — —
33–37 (vs. 1st quartile) 0.94 (0.89; 1.41) 0.24bmained in the Cox proportional hazards model that were
37–40 (vs. 1st quartile) 0.81 (0.59; 0.92) 0.035linked to CVE with P  0.05 were: CRP, age, albumin,
40 (vs. 1st quartile) 0.49 (0.27; 0.79) 0.007
history of CVE, serum homocysteine. Gender was kept History of CVE
No 1 — —in the model. Assumptions of Cox models (log-linearity,
Yes 4.06 (1.61; 7.32) 0.01proportionality of risk in time) were met in this analysis.
aCox model is adjusted for genderRelative risks (RR) and their 95% confidence intervals b Non-significant at 
  5%
(95% CI) of CVE for each variable in the Cox model
are displayed in Table 4, along with P values.
maining in the Cox proportional hazards model, that is,Influence of CRP on survival
those linked to death with P  0.05, were CRP, age,
Ninety-two patients (38.3%) died during the follow- albumin, and a history of CVE. Gender was kept in
up period, 41 (45%) of cardiovascular disease. CRP lev- the model. Assumptions of Cox models (log-linearity,
els were higher in patients who died during the study proportionality of risk in time) were met in this analysis.
period (25  12 vs. 5  8 mg/L; P  0.003). Relative risks (RR) and their 95% confidence intervals
In univariate analysis, age (P  0.0001), a past history (95% CI) of death for each variable in the Cox model
of cardiovascular disease (P  0.0001), smoking status are displayed in Table 5, along with P values.
(P  0.05), diabetes mellitus (P  0.04), high fibrinogen
concentration (P  0.09), tHcy (P  0.01), CRP (P 
DISCUSSION0.003) and low albumin concentration (P  0.008) were
associated with death. There is a high incidence of cardiovascular complica-
tions in the PD population. In our study, the cumulativeAfter backward stepwise selection, the variables re-
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risk for developing CVE was 10.8% within one year. patible materials seems to be the main cause of the burst
in acute phase response markers observed after the initi-Both traditional and non-traditional CV risk factors are
very prevalent and take into account this increased inci- ation of hemodialysis [9, 20, 22, 23]. Our study analyzed
the influence of pre-dialysis CRP concentrations as a pre-dence of atherosclerotic events. Nevertheless, our study
outlined the importance of non-traditional risk factors dictor of subsequent cardiovascular outcomes. Because
of the absence of effect of PD on CRP levels, these mea-such as acute phase response, malnutrition, and hyperho-
mocysteinemia over traditional CV risk factors in this sures are likely to reflect post-dialysis values. Moreover,
all patients started PD in a stable state, and although itpopulation.
Few studies have focused on the relationships between is not possible to exclude occult infection in patients with
elevated CRP, no patient had any evidence of infection.inflammation and CV outcomes in the restricted popula-
tion of end-stage renal disease patients on PD. Elevated Finally, pre-dialysis evaluation eliminated the role of peri-
tonitis and exit-site infections as confounding parametersCRP levels have been associated with carotid atheroscle-
rosis [15] and cardiac valve calcification [16] in the PD in the elevation of CRP.
We found a strong association between elevated CRPpopulation. Nevertheless, cross-sectional analysis such
as these can only be regarded as hypothesis-generating. levels and death. Such an association has been previously
reported in hemodialysis patients [9, 24, 25]. Neverthe-A number of weaknesses are inherent in this study de-
sign, including biases such as selection, survival, as well less, Owen and Lowrie did not find any relationship
between CRP and survival in a large cohort of hemodial-as confounding. Some prospective studies have been re-
cently published; Haubitz and Brunkhorst studied 34 PD ysis patients [26], and conflicting data have been reported
in the PD population [12, 27]. Discrepancies betweenpatients during 72 months for the occurrence of cardio-
vascular complications and found that the incidence of studies have been attributed to the variable extent of
adjustment for covariates in the different studies. Never-coronary artery disease was significantly increased in
patients with higher CRP levels [11]. Herzig et al, in a theless, in our study, CRP remains associated with death
even after adjustment for major potential confoundingprospective study including 50 PD patients, reported that
an elevated CRP was associated with an increased risk covariates in the proportional hazards model, especially
hemoglobin levels and markers of malnutrition. Our re-of myocardial infarction and a trend toward an increased
risk of both cardiovascular and all-cause mortality [12]. sults highly suggest that elevated CRP carries an inde-
pendent predictive risk of death in PD patients.Nevertheless, the small size of these study samples ham-
pered the relevance of their conclusions. Our study in a A strong relationship between CVE and both hypo-
albuminemia and hyperhomocysteinemia was found insingle-center large population confirms that elevated
CRP levels are predictive of cardiovascular complica- our PD patients, outlining the major role of non-tradi-
tional CV risk factors in this population. Several studiestions in PD patients. The RR for the occurrence of car-
diovascular complications increased gradually with CRP have demonstrated that CRP is inversely related to albu-
min levels [28–30]. Despite this relationship, we also iden-levels, and patients in the highest quartile of CRP con-
centrations had a fivefold increase in risk of CVE com- tified low albumin concentration as an independent risk
factor for CVE and death. Interestingly, there was nopared to those in the lowest quartile.
The mechanisms supporting the association between interaction between CRP and albumin in the increased
risk of CVE conferred by high CRP levels. By contrast,atherosclerotic complications and elevated CRP remain
unclear. CRP elevations may be a consequence of vascu- there are conflicting data concerning the role of hyper-
homocysteinemia as a cardiovascular risk factor in thelar injury with secondary release of proinflammatory cy-
tokines by monocytes and macrophages recruited into PD population [31, 32]. Some studies have suggested that
PD patients with the lowest tHcy, a condition frequentlyatherosclerotic plaques. Alternatively, CRP may reflect
chronic infection by infectious agents that have been associated with malnutrition, were at an increased risk
of cardiovascular complications and death [32]. In ourlinked with atherosclerosis progression, such as Chla-
mydia pneumoniae and cytomegalovirus [17]. This way, study, tHcy concentrations in the higher quartile con-
ferred a fourfold increase risk of CVE even after ad-CRP may be a marker of rather than an actor in the
progression of atherosclerosis. Nevertheless, recent evi- justment for nutrition markers. Otherwise, there was
no U-curve for tHcy as a cardiovascular risk factor indence suggests that CRP by itself may promote cardio-
vascular injury via activation of complement [18] and PD patients.
There are some limitations to our study. We studiedinduction of monocyte expression of tissue factor [19].
Contrary to hemodialysis, PD is not associated with the influence of a baseline CRP determination on the
occurrence of CVE in a population of patients startingan exacerbation of the acute phase response [20]. CRP
levels are significantly higher in patients receiving hemo- PD. Peritoneal dialysis may itself modify both traditional
and non-traditional cardiovascular risk factors [33, 34].dialysis as compared to healthy subjects and predialysis
end-stage renal disease patients [21]. The use of bioincom- Serial measurements of CRP in a longitudinal cohort
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and cardiovascular disease in chronic, stable renal transplant recipi-design would certainly provide a more precise estimate
ents: A prospective study. J Am Soc Nephrol 11:134–137, 2000
of cardiovascular risk conferred by elevated CRP in this 15. Zoccali C, Benedetto FA, Mallamaci F, et al: Inflammation is
associated with carotid atherosclerosis in dialysis patients. Creedpopulation.
Investigators. Cardiovascular Risk Extended Evaluation in Dial-Chronic inflammation, as reflected by elevated CRP
ysis patients. J Hypertens 18:1207–1209, 2000
levels, is frequent in patients starting PD and indepen- 16. Wang AY, Woo J, Wang M, et al: Association of inflammation
and malnutrition with cardiac valve calcification in continuousdently contributes to an increased incidence of CVE in
ambulatory peritoneal dialysis patients. J Am Soc Nephrol 12:1927–this population. These data lend support to the hypothe-
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